Summary
AAV gene therapy has a scalability challenge, to address this we have developed a novel self-silencing adenoviral system, TESSA®. With TESSA®, we can deliver all of the components necessary to efficiently manufacture contaminant-free AAV, in serum-free suspension HEK293 cells.
TESSA® is an E1/E3-deleted adenoviral vector with a modified Major Late Promoter (MLP). A TetR gene has been introduced into the late region with binding sites added in the MLP. This creates a negative feedback loop blocking the production of adenoviral structural proteins.
TESSA® can only replicate in the presence of the TetR inhibitor Doxycycline. When used for AAV production, in the absence of Doxycycline, no adenoviral particles are produced